Editorial policy

Sourcing

Every clinical claim is traced to one of the following:

• Peer-reviewed publications (NEJM, Lancet, Cell Metabolism, etc.)
• Registered trial protocols on ClinicalTrials.gov or international registries
• Regulatory documents (FDA labels, EMA EPAR, MHRA SmPC)
• Manufacturer press releases (clearly labeled as such)
• Recognized professional-society guidelines (ADA, AHA, EASD, OMA)

We do not cite Reddit, vendor websites, or unverified social media posts as sources of clinical information. We will cite clinician commentary or sell-side analyst forecasts when they help frame uncertainty — clearly labeled as opinion or projection, not fact.

Handling uncertainty

Where the evidence is not settled, we say so. Examples that appear throughout this site:

• Cross-trial comparisons of weight loss are labeled as cross-trial, with explicit caveats about population, duration, and design differences.
• Phase 2 results are not asserted as definitive; we note that Phase 3 readouts may modify them.
• Projected pricing and approval timelines are presented as analyst estimates, not facts.
• Mechanistic claims (e.g., why glucagon-receptor activation produces additional weight loss) are flagged as the leading hypothesis when not yet proven.

What we won't publish

• Specific dosing or treatment recommendations to readers.
• Reviews, recommendations, or affiliate links for gray-market "research peptide" vendors.
• Anecdote-only content or testimonials without supporting trial-grade evidence.
• Content generated entirely by AI tools without human editorial review and citation verification.
• Clickbait headlines that overstate what the underlying evidence shows.

Use of AI tools

AI assistance is used for editing, formatting, and summarization — not for sourcing or for generating clinical claims. Every fact and number on this site is verified against a primary source by a human editor before publication. AI-generated content that has not been source-verified does not get published.

Updates and corrections

When new evidence lands — a Phase 3 readout, a regulatory action, a label change — affected pages are reviewed within 72 hours and updated. Substantive revisions get a dated update note. Errors get a dated correction note at the bottom of the affected page.

We do not silently rewrite content. The published version history is preserved.

Independence and disclosure

Retatrutide Guide is independent. The site does not accept payment, samples, consulting agreements, or content contributions from Eli Lilly, Novo Nordisk, or any other pharmaceutical company.

When (and if) the site adopts affiliate or advertising revenue, those relationships will be disclosed site-wide and at the link/page level. See Medical review for related policies on conflicts of interest.

Reaching us

Editorial questions, corrections, and source suggestions are welcome. See the contact page.